Imatinib in the treatment of nephrogenic systemic fibrosis.
Nephrogenic systemic fibrosis is a disabling progressive condition that is being reported with increased frequency in patients with kidney disease. Treatment is extremely limited and largely supportive. We report a case of severe nephrogenic systemic fibrosis in a dialysis patient exposed to multiple doses of gadolinium who improved clinically and histologically with treatment with imatinib.
Chandran
Sindhu
S
Division of Nephrology, Stanford University, Stanford, CA 94305-5114, USA.
Petersen
Jeffrey
J
Jacobs
Charlotte
C
Fiorentino
David
D
Doeden
Katherine
K
Lafayette
Richard A
RA
D001549:Benzamides; D003287:Contrast Media / Q000009:adverse effects; D005260:Female; D005682:Gadolinium / Q000009:adverse effects; D006801:Humans; D000068877:Imatinib Mesylate; D007676:Kidney Failure, Chronic; D008875:Middle Aged; D054989:Nephrogenic Fibrosing Dermopathy / Q000139:chemically induced / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D006435:Renal Dialysis
D001549:Benzamides; D003287:Contrast Media; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D005682:Gadolinium